Upside – $LPCN +40% (Health Canada approves TLANDO for testosterone replacement therapy) – $APUS +9.4% (extends a high-volume rally tied to the BlockAssure agreement to build and operate the AssureChain insurance network) – $PENG +4.3% (Q4 beat and FY27 sales and EPS outlook topped prior guidance and Street expectations on accelerating AI-infrastructure demand) – CNQ …
Read in context ›Lipocine Stock (LPCN)
Track Lipocine stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
LPCN
Lipocine
healthcare
At close
$1.72
â–¼ -0.21 (-10.88%)
Oct 9, 4:00 PM ET
After-hours
$1.73
â–² +0.01 (+0.58%)
Oct 9, 7:58 PM ET
Market Cap
$14.18M
P/E Ratio
—
1Y Return
-45.40%
EPS (TTM)
-$1.86
Read the latest TheStreet Pro articles mentioning Lipocine, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning LPCN yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning